Sangui BioTech International Inc.

  • WKN: 906757
  • ISIN: US80105B1017
  • Land: Germany

Nachricht vom 14.02.2020 | 11:10

Sangui BioTech International Inc.: Significant cost reductions in the first half - year; Significant reduction of operating loss

DGAP-News: Sangui BioTech International Inc. / Key word(s): Half Year Results
14.02.2020 / 11:10
The issuer is solely responsible for the content of this announcement.


 

Sangui BioTech:

- Significant cost reductions in the first half - year

- Significant reduction of operating loss


Hamburg, February, 14 2020: In the first six months of fiscal year 2020 (to 30/06/2020) Sangui BioTech International Inc. achieved revenues from royalty income of USD 11,965. In the same period of the previous year the comparable revenue amounted to USD 55,367. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first six month of the year was significantly below the level of the same period of the previous year.

Responsible for this development were measures for the integration of the licensee, SastoMed GmbH into the Mölnlycke Group. In particular, the restructuring of the sales and distribution channels in the Mölnlycke Group has taken some time. Mölnlycke believes that these measures will bear fruit with respect to revenue.

As operating expenses decreased USD 104,507 or 50% to USD 104,396 during the period, six-month operating loss decreased USD 61,204 to USD 92,431 from the prior year. The reason for this was cost savings in connection with the closure of the Witten site.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



14.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.

GBC-Fokusbox

Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

Deutsche Lufthansa AG: Einigung über Lufthansa Stabilisierungspaket

30. Mai 2020, 00:04

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

29. Mai 2020